INTRODUCTION
The purpose of this document is to provide nuclear medicine practitioners with general guidelines on parathyroid scintigraphy, including, but not limited to, radiopharmaceuticals used to perform the study and generally accepted examination techniques.
II. GOAL
The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of parathyroid imaging.
III. DEFINITIONS
Primary hyperparathyroidism is characterized by increased synthesis and release of parathyroid hormone, which produces an elevated serum calcium level and a decline in serum inorganic phosphates. Asymptomatic patients are frequently identified by routine laboratory screening. The vast majority of cases of primary hyperparathyroidism (80-90%) are due to single hyperfunctioning adenomas. Multigland hyperplasia and double adenomas account for approximately 10 of cases, while parathyroid carcinomas occur in only 1-3% of cases of hyperparathyroidism. In general, parathyroid adenomas larger than 500 mg can be detected scintigraphically. Hyperplastic glands, can be detected but with less sensitivity than adenomas.
Dual phase or double phase imaging refers to acquisition of early and delayed images with 99m Tc sestamibi. Dual isotope or subtraction imaging refers to protocols using two different radiopharmaceuticals.
IV. EXAMPLES OF CLINICAL AND RESEARCH INDICATIONS

Indications for parathyroid scintigraphy include, but are not limited to the following:
A. While no published appropriateness criteria exist for parathyroid scintigraphy, parathyroid scintigraphy is specifically designed to localize parathyroid adenoma(s) or parathyroid hyperplasia in patients with hyperparathyroidism that is determined based on elevated parathyroid hormone (PTH) levels in the setting of an elevated serum calcium level. (1-8) .
B.
Localization of hyperfunctioning parathyroid tissue (adenomas or hyperplasia) in primary hyperparathyroidism. This is useful prior to surgery to help the surgeon localize the lesion, thus shortening the time of the procedure. In the past when surgery involved bilateral neck exploration, parathyroid scintigraphy was controversial. (1) (2) (3) (4) (5) (9) (10) (11) (12) . However, with present day minimally invasive parathyroidectomy, pre-operative parathyroid scintigraphy may be extremely useful in reducing the duration or extent of surgical exploration.
C. Localization of hyperfunctioning parathyroid tissue in patients with persistent or recurrent disease. Many of these patients will already have had one or more surgical procedures, making re-exploration more technically difficult. Also, ectopic tissue is more prevalent in this population, and pre-operative localization will likely increase surgical success, in part by helping to direct the surgical approach (6, (13) (14) (15) (16) .
D.
Localization of hyperfunctioning parathyroid tissue for intraoperative localization using a probe or a small camera. This can be helpful, particularly in patients with persistent or recurrent disease, especially in those who have undergone previous surgical exploration.
V. QUALIFICATIONS AND RESPONSIBILITY OF PERSONNEL
Please see SNM Procedure Guideline for General Imaging Tcsestamibi. The administered radioactivity, given orally, ranges from 7.5-22 MBq (200-600 µCi).
VI. PROCEDURE/SPECIFICATIONS OF THE EXAMINATION
D.
Protocol/Image Acquisition Tcsestamibi images is performed (3, 8, 10, 12, 17, 22, 24 Tc-pertechnetate (dual phase), the two sets of images (early and delayed) are inspected visually. Abnormal parathyroid tissue usually appears as an area of increased uptake, and becomes more prominent on the delayed images. However, some lesions (10-15%) will show washout of tracer by 2-21/2 h. Many hyperplastic glands show rapid washout. Washout of tracer from adenomas is variable. SPECT images may reveal lesions not seen on planar images, and SPECT/CT images may provide better localization of abnormal findings on functional imaging.
Dual isotope protocols 99m
Tc-sestamibi/ 99m Tc-pertechnetate and 99m Tc-sestamibi/ 123 I-iodide images should be inspected visually as well as evaluated with computer subtraction and/or with rapid alternating display of images (cine). Abnormal parathyroid tissue appears as an area of relatively increased 99m Tc-sestamibi uptake. Computer subtraction may be useful in cases with equivocal visual findings.
F. Interventions None
VII. DOCUMENTATION/REPORTING
In addition to patient demographics, the report should include the following information:
A. Indication for the study 
VIII. EQUIPMENT SPECIFICATION
Any properly functioning gamma camera may be used to acquire the images in parathyroid scintigraphy. Parallel-hole collimation is the standard for imaging the neck and mediastinum, though pinhole collimation can be used for better evaluation of the neck.
Computer acquisition is necessary for the dual-radiopharmaceutical technique with subtraction. It is often helpful for qualitative visual analysis in single radiopharmaceutical studies as well.
IX. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION CONCERNS
See also the SNM Procedure Guideline for General Imaging
Gamma camera quality control will vary from camera to camera. Multiple spatial and energy window registration should be checked periodically if dual isotope studies are performed. For further guidance in gamma camera quality control, refer to the Society of Nuclear Medicine Procedure Guideline for General Imaging for routine quality control procedures for gamma cameras.
A. Sources of Error 1. Patient motion.
2. Image misregistration.
3. Adenomas or hyperplastic glands less than 600 mg in size are more difficult to detect (17).
4.
Ectopic adenomas can be difficult to detect; the entire neck as well as the upper mediastinum to the level of the heart should be imaged.
5. Thyroid lesions, such as adenomas and carcinomas, may be indistinguishable from parathyroid lesions.
6. Parathyroid carcinomas are indistinguishable from other parathyroid lesions.
7. Recently administered radiographic contrast material or thyroid hormone (within the previous 3-4 wk) may interfere with 123 I and pertechnetate imaging, and will therefore compromise the use of subtraction techniques. This is not a problem with dual phase sestamibi studies.
8. Previous thyroidectomy can be a problem, especially for precise lesion localization, mainly with the subtraction technique.
B. Issues Requiring Further Clarification
There is now a clear consensus that imaging with 99m Tc-sestamibi is superior to 201 Tl-chloride, 201 Tl-chlorideshould no longer be used. A few investigators have utilized 99m Tc-tetrofosmin; however, it is not clear if this agent is comparable to 99m Tc-sestamibi. There is still no consensus regarding subtraction imaging versus dual phase imaging. There is a developing consensus that SPECT and SPECT/CT are most useful, for improving precision of anatomical localization (17, 18, 19, 21) .
There is still controversy regarding the utility of this study as a pre-operative evaluation in primary hyperparathyroidism in patients who have not had prior surgery. However, there are now some data that these studies may shorten the operative time and reduce cost. In cases of residual or recurrent disease, these studies are clearly helpful.
There are some data emerging that 18 F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging may be useful in imaging parathyroid adenomas. PET studies are probably most useful in difficult cases where 99m Tcsestamibi or tetrofosmin have failed to localize the cause for a high PTH level. PET imaging would generally involve the use of F-18 FDG, or possibly C-11 methionine outside the U.S. Also of high importance in cases involving radioiodine administrations to the pregnant patient is the possible dose to the fetal thyroid, which takes up iodine after 10-13 weeks' gestation (29):
X. RADIATION SAFETY IN IMAGING
Gestational age (months) Fetal thyroid dose (per unit activity administered to the mother) mGy/MBq (rad/mCi) 3 2.7 (10) 4 2.6 (9.6) 5 6.4 (24) 6 6. Tcpertechnetate and a greater than 3 weeks interruption for 123 I-NaI.
XI.
